Adults and adolescents 12 years of age and older living with asthma may qualify for a clinical research study evaluating an investigational medication designed to help reduce asthma attacks and improve long-term disease control.
Asthma
Age Range:
12
Gender:
Male and Female
Location:
West Chester, Pennsylvania
About the Study
This research study is evaluating depemokimab, an investigational medication, to determine whether earlier treatment with this therapy may help reduce asthma exacerbations, improve symptom control, and slow lung function decline. Depemokimab is a type of biologic therapy designed to target inflammation associated with Type 2 asthma. Researchers will compare depemokimab to placebo to assess its effectiveness, safety, and tolerability.
Qualifications
You may be able to join if you:
- Are 12 years of age or older.
- Have been diagnosed with asthma for at least 2 years.
- Have had at least 2 asthma exacerbations in the past 3 years, including at least 1 in the past year.
FEATURED STUDIES
MDD Study
Adults 18 to 65 years of age with Major Depressive Disorder (MDD) may qualify for a clinical research study evaluating
Asthma
Adults and adolescents 12 years of age and older living with asthma may qualify for a clinical research study evaluating
Chronic Obstructive Pulmonary Disease (COPD)
Adults 40–75 who have COPD and experienced a flare-up in the past year may qualify for a study evaluating an
Post-Traumatic Stress Disorder (PTSD)
Adults 18 and older living with post-traumatic stress disorder (PTSD) may qualify for a clinical research study evaluating an investigational
Bronchiectasis
Individuals with bronchiectasis who experience frequent flare-ups or ongoing respiratory symptoms may qualify for a research study evaluating a home
Hypertension & Type 2 Diabetes
Researchers are studying an investigational medication to see how effective it may be in reducing risk of heart failure for